The Conversation (0)
Neos Therapeutics Launches Adzenys ER (amphetamine) Extended-Release Oral Suspension in U.S. for the Treatment of ADHD
Feb. 26, 2018 08:40AM PST
Pharmaceutical InvestingNeos Therapeutics (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced the U.S. launch of Adzenys ERTM (amphetamine) Extended-Release Oral Suspension, making it Neos’ third ADHD product launch in less than two years. As quoted in the press release: “The launch of …
Neos Therapeutics (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced the U.S. launch of Adzenys ERTM (amphetamine) Extended-Release Oral Suspension, making it Neos’ third ADHD product launch in less than two years.
As quoted in the press release:
“The launch of Adzenys ER oral suspension is yet another example of our commitment to helping meet the different needs of patients with ADHD, their caregivers and healthcare professionals,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics. “Our growing ADHD Product Portfolio represents the strength of our unique technology platform and our ability to develop, manufacture and commercialize products.”
